640 related articles for article (PubMed ID: 31270752)
1. Onasemnogene Abeparvovec: First Global Approval.
Hoy SM
Drugs; 2019 Jul; 79(11):1255-1262. PubMed ID: 31270752
[TBL] [Abstract][Full Text] [Related]
2. Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy.
Blair HA
CNS Drugs; 2022 Sep; 36(9):995-1005. PubMed ID: 35960489
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacological and clinical profile of Onasemnogene Aveparvovec, the first gene therapy for spinal muscular atrophy (SMA)].
Atsumi A; Yoneda T; Tsuchida K; Kagawa Y; Tominaga S; Kawase K; Kikuchi N
Nihon Yakurigaku Zasshi; 2022; 157(1):53-61. PubMed ID: 34980814
[TBL] [Abstract][Full Text] [Related]
4. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
[TBL] [Abstract][Full Text] [Related]
5. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy.
Stevens D; Claborn MK; Gildon BL; Kessler TL; Walker C
Ann Pharmacother; 2020 Oct; 54(10):1001-1009. PubMed ID: 32204605
[TBL] [Abstract][Full Text] [Related]
6. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.
Al-Zaidy SA; Mendell JR
Pediatr Neurol; 2019 Nov; 100():3-11. PubMed ID: 31371124
[TBL] [Abstract][Full Text] [Related]
7. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
Mercuri E; Muntoni F; Baranello G; Masson R; Boespflug-Tanguy O; Bruno C; Corti S; Daron A; Deconinck N; Servais L; Straub V; Ouyang H; Chand D; Tauscher-Wisniewski S; Mendonca N; Lavrov A;
Lancet Neurol; 2021 Oct; 20(10):832-841. PubMed ID: 34536405
[TBL] [Abstract][Full Text] [Related]
8. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.
McMillan HJ; Proud CM; Farrar MA; Alexander IE; Muntoni F; Servais L
Expert Opin Biol Ther; 2022 Sep; 22(9):1075-1090. PubMed ID: 35437095
[TBL] [Abstract][Full Text] [Related]
9. Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy.
Schwartz M; Likhite S; Meyer K
Drugs Today (Barc); 2021 Jun; 57(6):387-399. PubMed ID: 34151905
[TBL] [Abstract][Full Text] [Related]
10. Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma).
Ogbonmide T; Rathore R; Rangrej SB; Hutchinson S; Lewis M; Ojilere S; Carvalho V; Kelly I
Cureus; 2023 Mar; 15(3):e36197. PubMed ID: 37065340
[TBL] [Abstract][Full Text] [Related]
11. Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy.
Naveed A; Calderon H
J Pediatr Pharmacol Ther; 2021; 26(5):437-444. PubMed ID: 34239394
[TBL] [Abstract][Full Text] [Related]
12. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy.
Kichula EA; Proud CM; Farrar MA; Kwon JM; Saito K; Desguerre I; McMillan HJ
Muscle Nerve; 2021 Oct; 64(4):413-427. PubMed ID: 34196026
[TBL] [Abstract][Full Text] [Related]
13. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG).
Finkel RS; Darras BT; Mendell JR; Day JW; Kuntz NL; Connolly AM; Zaidman CM; Crawford TO; Butterfield RJ; Shieh PB; Tennekoon G; Brandsema JF; Iannaccone ST; Shoffner J; Kavanagh S; Macek TA; Tauscher-Wisniewski S
J Neuromuscul Dis; 2023; 10(3):389-404. PubMed ID: 36911944
[TBL] [Abstract][Full Text] [Related]
14. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
Bitetti I; Lanzara V; Margiotta G; Varone A
Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.
Thomsen G; Burghes AHM; Hsieh C; Do J; Chu BTT; Perry S; Barkho B; Kaufmann P; Sproule DM; Feltner DE; Chung WK; McGovern VL; Hevner RF; Conces M; Pierson CR; Scoto M; Muntoni F; Mendell JR; Foust KD
Nat Med; 2021 Oct; 27(10):1701-1711. PubMed ID: 34608334
[TBL] [Abstract][Full Text] [Related]
16. Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy.
Aslesh T; Yokota T
Cells; 2022 Jan; 11(3):. PubMed ID: 35159227
[TBL] [Abstract][Full Text] [Related]
17. Zolgensma - one-time gene therapy for spinal muscular atrophy.
Med Lett Drugs Ther; 2019 Jul; 61(1577):113-114. PubMed ID: 31381549
[No Abstract] [Full Text] [Related]
18. Prevalence of Anti-Adeno-Associated Virus Serotype 9 Antibodies in Adult Patients with Spinal Muscular Atrophy.
Stolte B; Schreiber-Katz O; Günther R; Wurster CD; Petri S; Osmanovic A; Freigang M; Uzelac Z; Leo M; von Velsen O; Bayer W; Dittmer U; Kleinschnitz C; Hagenacker T
Hum Gene Ther; 2022 Sep; 33(17-18):968-976. PubMed ID: 35943879
[TBL] [Abstract][Full Text] [Related]
19. Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program.
Chand DH; Mitchell S; Sun R; LaMarca N; Reyna SP; Sutter T
Pediatr Neurol; 2022 Jul; 132():27-32. PubMed ID: 35605311
[TBL] [Abstract][Full Text] [Related]
20. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
Chand D; Mohr F; McMillan H; Tukov FF; Montgomery K; Kleyn A; Sun R; Tauscher-Wisniewski S; Kaufmann P; Kullak-Ublick G
J Hepatol; 2021 Mar; 74(3):560-566. PubMed ID: 33186633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
